Health Canada Approves Lecanemab for Early Alzheimer's Treatment

Health Canada has conditionally approved lecanemab, a new drug designed to slow the progression of earlystage Alzheimer's disease. This decision marks a significant development in Alzheimer's treatment, as lecanemab is the first medication in Canada that modifies the disease rather than just alleviating symptoms. Lecanemab works by targeting amyloid plaques in the brain, a hallmark of Alzheimer's. However, it is important to note that this drug is not a cure and will not restore lost memories. Patients eligible for treatment must have documented amyloid plaques and must undergo genetic testing for variants that may lead to side effects. The drug is administered via intravenous infusion every two weeks. Initial results indicate that it may take up to 18 months for noticeable benefits. While the approval is a step forward, experts are calling for further research to determine its overall effectiveness and impact on the healthcare system in Canada. The cost of lecanemab is approximately $26,000 a year in other countries, raising concerns about accessibility and insurance coverage in Canada.